Menarini Group – Product Pipeline Review – H2 2011 by GlobalMarketsDirect

VIEWS: 26 PAGES: 45

More Info
									   Menarini Group – Product Pipeline Review – H2 2011
                                                                                          Reference Code: GMDHC01648CDB

                                                                                                 Publication Date: NOV 2011




Menarini Group – Product Pipeline Review – H2 2011                                          GMDHC01648CDB / Published NOV 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                 Page(1)
Menarini Group – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 3
      List of Figures .................................................................................................................................................................................................... 4
Menarini Group Snapshot ......................................................................................................................................................................................... 5
      Menarini Group Overview................................................................................................................................................................................... 5
      Key Information .................................................................................................................................................................................................. 5
      Key Facts ........................................................................................................................................................................................................... 5
Menarini Group – Research and Development Overview.......................................................................................................................................... 6
      Key Therapeutic Areas ....................................................................................................................................................................................... 6
Menarini Group – Pipeline Review ............................................................................................................................................................................ 8
      Pipeline Products by Stage of Development ....................................................................................................................................................... 8
      Pipeline Products – Monotherapy ...................................................................................................................................................................... 9
      Pipeline Products – Combination Treatment Modalities .....................................................................................................................................10
Menarini Group – Pipeline Products Glance ............................................................................................................................................................11
      Menarini Group Clinical Stage Pipeline Products...............................................................................................................................................11
            Phase II Products/Combination Treatment Modalities .................................................................................................................................11
Menarini Group – Drug Profiles ...............................................................................................................................................................................12
      Amediplase .......................................................................................................................................................................................................12
            Product Description ....................................................................................................................................................................................12
            Mechanism of Action...................................................................................................................................................................................12
            R&D Progress .............................................................................................................................................................................................12
      MEN16132 ........................................................................................................................................................................................................13
            Product Description ....................................................................................................................................................................................13
            Mechanism of Action...................................................................................................................................................................................13
            R&D Progress .............................................................................................................................................................................................13
      Sabarubicin .......................................................................................................................................................................................................14
            Product Description ....................................................................................................................................................................................14
            Mechanism of Action...................................................................................................................................................................................14
            R&D Progress .............................................................................................................................................................................................14
      Sabarubicin + cisplatin ......................................................................................................................................................................................15
            Product Description ....................................................................................................................................................................................15
            Mechanism of Action...................................................................................................................................................................................15
            R&D Progress .............................................................................................................................................................................................15
Menarini Group – Pipeline Analysis .........................................................................................................................................................................16
      Menarini Group – Pipeline Products by Therapeutic Class ................................................................................................................................16
      Menarini Group - Pipeline Products By Target...................................................................................................................................................17
      Menarini Group – Pipeline Products by Route of Administration ........................................................................................................................18
      Menarini Group – Pipeline Products by Molecule Type......................................................................................................................................19
Menarini Group – Recent Pipeline Updates ............................................................................................................................................................20
Menarini Group – Company Statement ....................................................................................................................................................................21
Menarini Group – Locations And Subsidiaries .........................................................................................................................................................22
      Head Office .......................................................................................................................................................................................................22
      Other Locations & Subsidiaries .........................................................................................................................................................................22
Recent Developments .............................................................................................................................................................................................24
            Dec 07, 2010: Menarini Completes Enrollment And Treatment Phase In Phase II Osteoarthritis Study.......................................................24
            Jun 01, 2002: Preparation For Phase III Clinicals: ProMetic And Menarini Biotech Achieve Milestone For Amediplase Manufacture ..........24




Menarini Group – Product Pipeline Review – H2 2011                                                                                                          GMDHC01648CDB / Published NOV 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                                                Page(2)
Menarini Group – Product Pipeline Review



            Jun 01, 1997: A Report From The European Organization For Research And Treatment Of Cancer, Early Clinical Studies Group .............25
Financial Deals Landscape......................................................................................................................................................................................26
      Menarini Group, Deals Summary ......................................................................................................................................................................26
Menarini Group, Pharmaceuticals & Healthcare, Deal Details..................................................................................................................................27
      Asset Transactions............................................................................................................................................................................................27
            PLIVA Sells AWD Manufacturing Plant In Germany ....................................................................................................................................27
      Partnerships .............................................................................................................................
								
To top